 |
 |
 |
| 24小時(shí)熱門(mén)版塊排行榜 |
- >論壇更新日志 (5919)
- >考研 (2784)
- >導(dǎo)師招生 (2377)
- >蟲(chóng)友互識(shí) (389)
- >文獻(xiàn)求助 (372)
- >碩博家園 (197)
- >休閑灌水 (173)
- >招聘信息布告欄 (108)
- >考博 (107)
- >基金申請(qǐng) (88)
- >博后之家 (72)
- >綠色求助(高懸賞) (51)
- >論文投稿 (50)
- >材料綜合 (25)
- >外文書(shū)籍求助 (18)
- >教師之家 (16)
 |
 |
 |
||
 |
 |
 |
 |
 |
| 1 | 1/1 | 返回列表 |
| 查看: 413 | 回復(fù): 0 | ||
西點(diǎn)6688木蟲(chóng) (正式寫(xiě)手)
|
[求助]
各位大神，求助一段話(huà)的翻譯，謝謝！~薈萃分析
|
|
RESULT We summarized 20 trials carried out in metastatic melanoma (MM), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) patients receiving anti-PD-1/PD-L1 antibodies (4230 MM, 1417 NSCLC and 312 RCC patients). Positive PD-L1 MM patients showed a significant decrease (53%) in the risk of mortality vs. negative cases with no heterogeneity. Furthermore, SORRs were 45% and 27% in PD-L1 positive and negative patients, respectively, and SOR indicates a significant difference in term of responses: 2.14 (95% CI: 1.65, 2.77), with low between-study heterogeneity (I2= 35%). Furthermore, results from randomized clinical trials on MM showed that PD-L1 expression is significantly associated with greater clinical response rates to anti-PD1 treatments (SOR 1.89; 95%CI: 1.35, 2.64) but not to other treatments (SOR 0.96; 95%CI: 0.5, 1.87). 因?yàn)槭撬C萃學(xué)分析，有些術(shù)語(yǔ)不理解，望專(zhuān)業(yè)人士點(diǎn)播，謝謝！原文網(wǎng)址： https://www.ncbi.nlm.nih.gov/pubmed/26895815 |
回復(fù)此樓» 猜你喜歡
315分 085602 求調(diào)劑
已經(jīng)有3人回復(fù)
-
求調(diào)劑，一志愿鄭州大學(xué)材料與化工專(zhuān)碩，英二數(shù)二342分，求老師收留
已經(jīng)有4人回復(fù)
-
285求調(diào)劑
已經(jīng)有8人回復(fù)
-
324求調(diào)劑
已經(jīng)有8人回復(fù)
-
一志愿華南師范大學(xué)-22408計(jì)算機(jī)-292分-求華南師范大學(xué)調(diào)劑
已經(jīng)有4人回復(fù)
-
材料調(diào)劑
已經(jīng)有9人回復(fù)
-
321求調(diào)劑
已經(jīng)有12人回復(fù)
-
調(diào)劑求助
已經(jīng)有4人回復(fù)
-
22408 266求調(diào)劑
已經(jīng)有3人回復(fù)
-
266分，一志愿電氣工程，本科材料，求材料專(zhuān)業(yè)調(diào)劑
已經(jīng)有4人回復(fù)
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 西點(diǎn)6688 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 總分328生物與醫(yī)藥考數(shù)學(xué)求調(diào)劑 +3 | aaadim 2026-04-02 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 385分 生物學(xué)（071000）求調(diào)劑 +6 | qf626 2026-04-01 | 6/300 |
|
|
|
[考研] 322求調(diào)劑 +5 | 熹僖XX 2026-03-31 | 6/300 |
|
|
|
[考研] 303求調(diào)劑 +8 | DLkz1314. 2026-03-30 | 8/400 |
|
|
|
[考研] 085602化學(xué)工程268分蹲調(diào)劑 +8 | 月照花林。 2026-04-01 | 8/400 |
|
|
|
[考研] 292求調(diào)劑 +17 | 木蟲(chóng)er12138 2026-04-01 | 17/850 |
|
|
|
[考研] 0703求調(diào)劑 +4 | zizimo 2026-03-31 | 4/200 |
|
|
|
[考研] 283求調(diào)劑 +9 | A child 2026-03-28 | 9/450 |
|
|
|
[考研] 一志愿南昌大學(xué)324求調(diào)劑 +7 | hanamiko 2026-03-30 | 7/350 |
|
|
|
[考研] 一志愿北交材料工程總分358 +5 | cs0106 2026-04-01 | 7/350 |
|
|
|
[考研] 化學(xué)0703 調(diào)劑 306分 一志愿211 +12 | 26要上岸 2026-03-28 | 12/600 |
|
|
|
[考研] 0856材料化工調(diào)劑 總分330 +18 | zhubinhao 2026-03-27 | 18/900 |
|
|
|
[考研] 311（085601）求調(diào)劑 +12 | liziyeyeye 2026-03-28 | 13/650 |
|
|
|
[考研] 0856求調(diào)劑 +9 | 楒桉 2026-03-28 | 9/450 |
|
|
|
[考研] 343求調(diào)劑 +8 | 愛(ài)羈絆 2026-03-28 | 8/400 |
|
|
|
[考研] 287求調(diào)劑 +17 | land xuxu 2026-03-26 | 17/850 |
|
|
|
[考研] 抱歉 +4 | 田洪有 2026-03-30 | 4/200 |
|
|
|
[考研] 0703 化學(xué) 求調(diào)劑，一志愿山東大學(xué) 342 分 +7 | Shern—- 2026-03-28 | 7/350 |
|
|
|
[考研] 394求調(diào)劑 +3 | 好事多磨靜候佳?/a> 2026-03-26 | 5/250 |
|
|
|
[考研] 一志愿上海理工能源動(dòng)力（085800）310分求調(diào)劑 +3 | zhangmingc 2026-03-27 | 4/200 |
|